Madopark Quick Mite (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter lacking in Parkinson's disease. Benserazide blocks the peripheral enzyme that would otherwise convert levodopa outside the brain, ensuring more levodopa reaches the central nervous system for dopamine synthesis.

The dosage of Madopark Quick Mite is individualized by the prescribing clinician based on disease severity, patient age, and response to therapy. Only a qualified healthcare professional should determine the appropriate dose and titration schedule.

Safety data for levodopa/benserazide in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Madopark Quick Mite combines levodopa with benserazide, offering higher central dopamine availability than levodopa alone. Compared with dopamine agonists, it provides more potent symptom control but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Madopark Quick Mite is taken orally with a full glass of water, usually on an empty stomach to improve absorption. Patients should follow the timing and dosing instructions provided by their healthcare professional and avoid taking it with high‑protein meals that may interfere with levodopa uptake.

Serious risks include neuroleptic malignant syndrome, severe hypotension, cardiac arrhythmias, and psychotic reactions such as hallucinations. Patients should be monitored closely for any sudden changes in mental status, blood pressure, or heart rhythm, and seek immediate medical attention if severe symptoms occur.

Patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors or those with uncontrolled narrow‑angle glaucoma, as it may exacerbate intra‑ocular pressure.